Class A
ISIN: LU1491986011
CATEGORY: Sector Equity Biotechnology
KEY INFORMATIONat 28.07.2021
Net Asset Value214,94 EUR
Fund Size (mln)19.953.314 EUR
Launch Date 2 ott 2012
MANAGEMENT INFORMATION
SicavPHARUS SICAV
Management CompanyPHARUS MANAGEMENT LUX SA
Investment ManagerPharus Asset Management SA
DOCUMENTS
N.A.
RISK & REWARD PROFILE
Lower Risk
Highest Risk
Potentially lower return
Potentially higher return
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
INVESTMENT OBJECTIVE
The sub-fund aims to achieve growth by investing in equities or similar securities issued by biopharmaceutical companies that are at the forefront of innovation in the medical sector. The sub-fund will invest at least two-thirds of its total assets in equities issued by companies operating in this sector.
MANAGER COMMENT
The sub-fund registered a positive performance of +5.43% in June, thus bringing the year-to-date performance to + 6.17%.
The sub-fund invests in companies in the pharmaceutical, medical and biotechnology sectors, with a particular interest in the latest technological and scientific innovations.
In June, we also rebalanced the fund by equipping small-medium companies operating in the biotechnology and medical innovation sector.
The positive performance was driven by the small cap biotech component, in particular some companies showed performances above + 100%.
At the geographic allocation level, we remain focused on the US market while maintaining full hedging against the EUR / USD exchange rate.
PERFORMANCE
Last updated on 28.07.2021
ASSET ALLOCATION
*
No coverage or derivatives are included
CURRENCY ALLOCATION
*
No coverage or derivatives are included
COUNTRY ALLOCATION
TOP TEN HOLDING
Invesco Nasdaq Biotech 2.57 %
Intellia Therapeutics Inc 1.14 %
Editas Medicine Inc 0.91 %
Anavex Life Sciences Corp 0.89 %
Beam Therapeutics Inc 0.87 %
Mannkind Corp 0.78 %
Translate Bio Inc 0.78 %
Ocugen Inc 0.76 %
Macrogenics Inc 0.76 %
Twist Bioscience Corp 0.7 %
SECTOR ALLOCATION
Current risk profile selected: